Fluorine in Medicinal Chemistry: In Perspective to COVID-19

02 March 2022, Version 1
This content is a preprint and has not undergone peer review at the time of posting.


Over two years into the outbreak of COVID-19, the quest for effective and economical drugs has become starkly clear to reduce the risk of progression of coronavirus disease. A number of drugs have been investigated and they can be taken orally at home and be used after exposure to SARS-CoV-2 or at the first sign of COVID-19. Fluorinated oral anti-COVID-19 drugs—including Paxlovid, the first oral tablet for the treatment of COVID-19—is an important subgroup. Fluorine has been widely used in pharmaceuticals market and can lead to improved selectivity indices, increased lipophilicity, greater metabolic stability, and in this case the improved anti-COVID-19 efficacy. In this mini-review, we will give an update on fluorinated anti-COVID-19 drugs by providing the key information and current knowledge of these drugs, including chemical structure, drug metabolism and pharmacokinetics, and mechanism of action.


Oral drug


Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.